(Alliance News) - AstraZeneca PLC on Monday said the US Food & Drug Administration has accepted and granted priority review to a supplemental biologics licence application for Ultomiris as a treatment for adults with immunoglobulin A nephropathy. Read More
(Alliance News) - AstraZeneca PLC on Friday said a Truqap combination has been approved by the US Food & Drug Administration as a first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer. Read More
(Alliance News) - The FTSE 100 ended the week on the front foot as Iran claimed a deal with the US has "never been closer", while investors were glued to dealing screens as trading in SpaceX kicked off. Read More
(Alliance News) - AstraZeneca PLC on Monday announced positive results from the Vista and Solstice phase IIb trials of elecoglipron, an oral small molecule GLP-1 receptor agonist. Read More
(Alliance News) - GSK agrees to buy US cancer treatment firm Nuvalent for USD10.6 billion, AstraZeneca advances its own weight-loss treatment while Bellway reports an "increasingly challenging" housing market. Read More
(Alliance News) - AstraZeneca PLC could be forced to withhold new medicines from the UK and Europe unless governments pay more for innovative drugs, Chief Executive Officer Pascal Soriot told the Financial Times in an interview published on Saturday. Read More
(Alliance News) - The FTSE 100 clung on to modest gains on Friday despite weak mining stocks, but Wall Street headed south after stronger-than-expected jobs data increased chances of a rate hike across the pond. Read More
(Alliance News) - Worldwide Healthcare Trust PLC on Friday said pharma company AstraZeneca PLC was its top contributor to its portfolio performance while surgical equipment firm Stryker Corp was the top detractor. Read More
(Alliance News) - BSF Enterprise on Tuesday saw its shares rise after the publication of a paper on one of its subsidiaries' synthetic leather products. Read More
(Alliance News) - AstraZeneca PLC on Monday posted positive phase-three trial results for a combination of its drugs Imfinzi and Imjudo to treat a form of liver cancer. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - AstraZeneca PLC on Friday announced that the CARES phase 3 clinical programme did not meet a primary endpoint, but noted insightful data. Read More
(Alliance News) - Stock prices in London opened higher on Friday, amid renewed hope for a deal between the US and Iran, which is reportedly awaiting the nod from President Donald Trump. Read More